{"schema_version":"secwatch.filing_event.v1","accession":"0000075252-22-000055","form_type":"8-K","ticker":"ACH","cik":"0000075252","company_name":"ACCENDRA HEALTH INC/VA/","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.501575+00:00","generated_at":"2026-06-22T16:00:52.236117+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Owens & Minor Q3 GAAP EPS $0.16 vs $0.58 YoY; adjusted EBITDA margin up 140 bps","bullets":["GAAP net income $12.5M ($0.16 EPS) vs $44.1M ($0.58 EPS) in Q3 2021; adjusted EPS $0.41 vs $0.74.","Revenue $2,497M, nearly flat YoY; adjusted EBITDA $127M, margin up 140 bps.","Patient Direct segment revenue grew 142% (11.4% pro forma for Apria); CPAP opportunities captured.","Products & Healthcare Services segment challenged by delayed customer reorders; accelerating key initiatives.","Generated $69M cash from operations in the quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0000075252-22-000055","json":"https://secwatch.observer/filing/0000075252-22-000055.json","markdown":"https://secwatch.observer/filing/0000075252-22-000055.md","text":"https://secwatch.observer/filing/0000075252-22-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/75252/000007525222000055/0000075252-22-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/75252/000007525222000055/omi-20221102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T16:00:52.236117+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60e69343a7c4ab2168b8d10c6208df0a88326834","claim":"ACCENDRA HEALTH INC/VA/ reported the third quarter ended September 30, 2022 results: revenue $2,497, net income $12.5, EPS $0.16.","evidence_excerpt":"as our execution and market conditions improve,” Pesicka concluded. Financial Summary (1) ($ in millions, except per share data) 3Q22 3Q21 YTD 2022 YTD 2021 Revenue $2,497 $2,502 $7,404 $7,318 Operating income, GAAP $60.2 $62.9 $196.4 $306.5 Adj. Operating Income, Non-GAAP $83.4 $79.3 $301.9 $357.5 Net income, GAAP $12.5 $44.1 $80.4 $179.6 Adj. Net","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/75252/000007525222000055/0000075252-22-000055-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$2,497"},{"label":"Net income","value":"$12.5"},{"label":"EPS","value":"$0.16"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}